BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10367745)

  • 1. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
    Luo FR; Wyrick SD; Chaney SG
    Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.
    Luo FR; Wyrick SD; Chaney SG
    Cancer Chemother Pharmacol; 1999; 44(1):29-38. PubMed ID: 10367746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotransformations of oxaliplatin in rat blood in vitro.
    Luo FR; Wyrick SD; Chaney SG
    J Biochem Mol Toxicol; 1999; 13(3-4):159-69. PubMed ID: 10098901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
    Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
    Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
    Luo FR; Wyrick SD; Chaney SG
    Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin.
    Luo FR; Yen TY; Wyrick SD; Chaney SG
    J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):345-56. PubMed ID: 10219677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
    Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
    Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.
    Thompson DC; Vaisman A; Sakata MK; Wyrick SD; Holbrook DJ; Chaney SG
    Cancer Chemother Pharmacol; 1995; 36(5):439-47. PubMed ID: 7634386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).
    Chaney S
    Int J Oncol; 1995 Jun; 6(6):1291-305. PubMed ID: 21556672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.
    Screnci D; Er HM; Hambley TW; Galettis P; Brouwer W; McKeage MJ
    Br J Cancer; 1997; 76(4):502-10. PubMed ID: 9275028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.
    Petros WP; Chaney SG; Smith DC; Fangmeier J; Sakata M; Brown TD; Trump DL
    Cancer Chemother Pharmacol; 1994; 33(4):347-54. PubMed ID: 8281629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible correlation between ormaplatin biotransformations and neurotoxicity.
    Sakata M; Chaney SG; Spriggs DR
    Oncol Res; 1995; 7(2):67-71. PubMed ID: 7579729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
    Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
    Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
    Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
    Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
    Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.
    Mauldin SK; Gibbons G; Wyrick SD; Chaney SG
    Cancer Res; 1988 Sep; 48(18):5136-44. PubMed ID: 3409241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma.
    Thompson DC; Wyrick SD; Holbrook DJ; Chaney SG
    Cancer Res; 1995 Jul; 55(13):2837-46. PubMed ID: 7796411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.
    Holmes J; Stanko J; Varchenko M; Ding H; Madden VJ; Bagnell CR; Wyrick SD; Chaney SG
    Toxicol Sci; 1998 Dec; 46(2):342-51. PubMed ID: 10048138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.